Guía OncoSur de Cáncer de mama 82 > Pacientes candidatas a recibir tratamiento neoadyuvante con enfermedadHER2+, basado en antraciclina + taxano + tratamiento anti-HER2 (pertuzumab + trastuzumab): – Pacientes con cáncer de mama con tamaño tumoral ≥ 2 cm, o – Pacientes con cualquier afectación ganglionar clínica de la axila al diagnóstico. BIBLIOGRAFÍA RECOMENDADA – Albanell J, Ciruelos E, de la Haba J, Martín M, Muñoz Molina B, de Salas-Cansado M, et al. Estimated Costs of Locoregional and Metastatic Recurrences in Patients with HER2+ Breast Cancer in Spain. ISPOR 19th Annual European Congress. 29 october - 2 november 2016. Vienna, Austria. – Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-19. – Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85. – Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72. – Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52. – Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-84. – Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32. – Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640-7. – Gianni L, Pienkowski T, Im Y-H, Tseng LM, Liu MC, Lluch A, et al. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). J Clin Oncol. 2015;33(Suppl); abstr 505. – Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869-78. – Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta- analysis. J Natl Cancer Inst. 2005;97:188-94. – Von Minckwitz G, Procter M, Azambuja E, Zardavas D, Benyunes M, Viale G, et al., for the APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumabin Early HER2-Positive Breast Cancer. NEJM. 2017;377:122-31. – Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al., for the KATHERINE Investigators. Trastuzumab Emtansine for ResidualInvasive HER2-Positive Breast Cancer. NEJM. 2019;14;380(7): 617-28. – Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11:718-9. – Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-84. – Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-34.
RkJQdWJsaXNoZXIy MTQzMjMwMg==